Stapokibart injection for adults with moderate-to-severe atopic dermatitis
Looks at how safe and effective stapokibart is in adults with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chengdu Kangnuoxing Biopharma,Inc.
- Trial code
- NCT07544862
- Record updated
- 10 June 2026
- Original description
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.Read full original descriptionShow less
A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Inclusion: Trial participants aged 18 years or older at baseline, with no restrictions on gender; Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Exclusion: Known history of allergic reaction to Stapokibart Injection; Trial participants with hematologic malignancies; Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study; Trial participants currently or plan participating in any interventional clinical trial; Women with pregnant.